Asset Details
Do you wish to reserve the book?
Treatment strategies for recurrent ovarian cancer in older adult patients in Japan: a study based on real-world data
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Treatment strategies for recurrent ovarian cancer in older adult patients in Japan: a study based on real-world data
Do you wish to request the book?
Treatment strategies for recurrent ovarian cancer in older adult patients in Japan: a study based on real-world data
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Treatment strategies for recurrent ovarian cancer in older adult patients in Japan: a study based on real-world data
2020
Overview
Background/objectiveElderly patients with cancer are often at risk for undertreatment because of frailty, an aging-specific problem. However, current real-world conditions of recurrent ovarian cancer treatment in elderly patients remain unclear. This study aimed to clarify treatment patterns in elderly patients with recurrent ovarian cancer.Patients and methodsWe used an ovarian cancer database containing the diagnosis and initial therapy of all patients at the National Cancer Center Hospital in Japan from 2007 to 2014. Patients were stratified into the platinum-sensitive group and the platinum-resistant group. We retrospectively assessed chemotherapy use in patients aged ≤ 64, 65–69, 70–74, 75–79, and ≥ 80 years.ResultsAmong 253 patients (sensitive group: 135; resistant group: 118), by age group 91%, 95%, 100%, 100%, and 100% received chemotherapy in the sensitive group, and 79%, 67%, 50%, 29%, 0% received chemotherapy in the resistant group, respectively. In the resistant group, the percentage of patients aged 70–74 or 75–79 years who received chemotherapy was significantly lower than the percentage among patients aged ≤ 64 years, respectively (p = 0.01, p = 0.01). In multivariate analysis, age ≥ 70 years (odds ratio [OR], 4.412; 95% confidence interval (CI), 1.628–11.959; p = 0.004) and platinum-free interval < 3 months (OR, 3.434; 95% CI, 1.401–8.399; p = 0.007) were inversely associated with chemotherapy use.ConclusionsDoctors and patients did not consider chemotherapy in patients aged ≥ 70 years with platinum-resistant disease. Older age was independently and inversely associated with chemotherapy use in platinum-resistant ovarian cancer. Our results highlight the importance of demographic information in clinical decision-making for elderly patients.
Publisher
Springer Nature B.V
Subject
